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Priming with low doses of methyl-CCNU reduce the toxicity of high
doses of methyl-CCNU and melphalan, and increase the lifespan of mice
implanted with Lewis lung carcinoma
A. Zimber, K. Perk & I. Livnat
Department ofAnimal Science and Koret School of Veterinary Medicine, Faculty ofAgriculture, P.O. Box 12, Rehovot 76100,
Israel.
Summary Pretreatment of mice with low doses of methyl-CCNU was shown to reduce the toxicity of lethal
doses of methyl-CCNU or melphalan administered one or two days following the low dose. There was an
increase in survival rate, body weight, thymus and kidney wet weight. Tissue morphology was less affected in
the primed mice as compared to mice receiving the high dose or a high-low dose combination. In mice
implanted s.c. with Lewis lung carcinoma, priming with 5 mgkg 1 methyl-CCNU 2 days before injection of a
very high (35mgkg-1) dose significantly increased the lifespan as compared to treatment with the high dose
alone or with high-low dose combination. When the dose of methyl-CCNU was further increased to
40mgkg-1 toxic death occurred, which was, however, significantly reduced by 'priming' with the low dose
given. When low-high dose combination was used twice (the high dose was given on day 7 or 9, and 18 or 20
after tumour inoculation), priming with 5mgkg-1 (but not with 10mgkg-1) two days prior to the high dose
was beneficial in reducing toxic death (in two experiments) and either increasing lifespan or not significantly
increasing it. In no case was there protection of the tumour by the low-high dose combinations.
Toxicity of certain anti-cancer drugs may be significantly
reduced by the administration of low doses of the same or
another cytotoxic drug (1 to 7 days) prior to the high dose.
The optimal time interval between treatments is dependent
on the specific drug combination and the animal species
investigated (Millar et al., 1975; 1978a, b). This has been
demonstrated in healthy and in tumour-bearing animals, and
in the last case a beneficial effect of low-high dose
combinations was observed (Millar and McElwain, 1978c;
Millar et al., 1980; Rose et al., 1975). Our own studies with
methyl-CCNU (NSC-95441; 1-(2-chloroethyl)-3-(4-methyl-
cyclohexyl)-1-nitroso-trans-urea), a nitrosourea compound
and a very effective anti-cancer drug in experimental
animals and man, revealed its unique properties in curing a
wide variety of experimental leukaemias (meningeal guinea
pig leukaemia; B and T myelogenous leukaemia, viral and
radiation-induced mouse leukaemias) even when administered
in a single dose (Peled et al., 1982; Perk et al., 1974; 1977).
Methyl-CCNU is, however, very toxic, causing both acute
killing of blood forming bone marrow cells and epithelial
cells along the gastrointestinal tract. It also causes delayed
toxicity to other tissues such as the kidney tubular epi-
thelium and the epithelium of the eye lens. In our own
experiments with mice, rats and chickens we have demon-
strated damage to the testicular germinal cells; a delayed and
sustained effect on the kidney tubular epithelium resulting
in polydipsia and polyuria and an alteration in calcium and
phosphorus metabolism; and the formation of eye lenticular
cataracts 4 to 6 months after cessation of treatment with
methyl-CCNU (Zimber & Perk, 1978; 1979; Zimber et al.,
1980).
The purpose of this investigation was to test whether the
toxicity of methyl-CCNU might be reduced by pretreatment
with low doses of the drug, and if the combination of low
and high doses of methyl-CCNU may be beneficial in the
treatment of tumour-bearing mice.
Materials and methods
Mice
Inbred male C57B1 mice were used in all the experiments.
They were maintained in an air conditioned room at
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24+1°C, with 12h light/dark cycle, given mouse chow and
water ad libitum.
Drugs
Mice were treated with methyl-CCNU and melphalan at the
age of 8-10 weeks. Methyl-CCNU was first dissolved in
ethanol; mulgofen (polyoxyethylated vegetable oil, EL-620,
GAF Corp., NY) was then added, and finally this solution
was brought to volume with sterile 0.9% saline (1:1:16 v/v,
respectively). Also, 100mg melphalan (Alkeran) were
dissolved in 1 ml acid alcohol and diluted in 9ml buffer
(materials supplied by Burroughs Wellcome and Co.,
London). Both drugs were injected i.p. (in 0.2 to 0.4ml) and
always from 9 to 11 a.m. Low doses of methyl-CCNU were 5
and 10mgkg-1. High doses of methyl-CCNU ranged from
30 to 55 mgkg-1. Melphalan was used in doses of 15 and
20mgkg-1. The time intervals between treatment with low
and high doses of drugs ranged between 1 to 3 days.
Lewis lung carcinoma
Lewis lung carcinoma (3LL) (kindly provided by Dr S.
Segal, the Weizmann Institute of Science, Rehovot) was
serially transplanted s.c. in C57B1 male mice. For
implantation, non-necrotic areas of the tumour were treated
with 0.25% trypsin and 0.1% DNAase, washed and diluted
in sterile PBS (pH7.4). Cell suspension containing 2 x 105 or
1 x 106 cells were inoculated s.c. on the abdomen. Eight days
after tumour inoculation mice were treated with low dose of
methyl-CCNU followed 2 days later by treatment with high
dose of this drug. Other experimental groups were treated
with the high dose alone, or with the high dose followed 2
days later by the low dose. Tumour size was determined by
measuring the longest two diameters with a caliper twice a
week. In all the experiments body weights were recorded
once a week. Organ wet weights (thymus, spleen, kidneys
and testes; also lung and s.c. tumours - in mice inoculated
with 3LL tumour cells) were recorded for all moribund and
dead mice and for those deliberately killed. These organs
were processed routinely for histological examination and
stained with haematoxylin and eosin.
Statistical analysis
Student's t-test, analysis of variance and a non-parametric
ranking test (Mann-Whitney, one tailed) were performed on
all the data (Snedecor & Cochran, 1967).
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Results
Survival studies
The effect oflow doses ofmethyl-CCNU administered prior to
sublethal and lethal doses in normal mice In a preliminary
experiment we investigated the effect of 10 mgkg- 1 of
methyl-CCNU given 3 days prior to 30mgkg-1 - a high
dose which was used by us previously in studies of experi-
mental leukaemia and drug toxicity (Peled et al., 1982; Perk
et al., 1974; Perk & Pearson, 1977; Zimber & Perk,
1978; 1979; Zimber et al., 1980). -This protocol did not
improve the condition of mice observed for a period of 10
weeks as compared to mice receiving the high dose alone or
a high-low dose combination. Thus, in all methyl-CCNU
treated groups body weights were significantly decreased,
polyuria was evident and plasma urea level was 50%
elevated (data not shown). Also, pretreatment with
5mgkg- 1 methyl-CCNU 3 days before the administration of
a lethal dose of 50mgkg- 1 of this drug did not alter
mortality rate. However, body weights, thymus and kidney
wet weights and morphology examined in mice surviving the
low-high (5/12 survivors) and high-low (4/12 survivors) dose
combinations 40 days after administration of the high dose
showed better recovery in the first group (Table I). Thus,
absolute weights of the thymus (mean+s.d.) were 40.2+7.4,
23.3 +8.0 and 46.1 +22.1 for controls, high-low and low-high
dose combinations, respectively. In Table I the number of
mice with pathologic changes in the kidney and thymus is
given. These were arbitrarily designated +, + or + +
depending on the mass of tissue affected and the severity of
changes: kidney tubular swellings and loss; thymus thinning
of the cortex and hypocellularity.
We then tested the effect of 5mgkg-1 of methyl-CCNU
administered one or two days before the lethal dose of
50mgkg-1. A protective effect of pretreatment with the low
dose was evident. showing significantly higher survival rate
(Figure 1). Mice treated with high-low dose combinations or
with high dose only showed 58 to 67% mortality within 3
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Figure 1 Percent survival of mice treated with low and high
lethal dose combinations of methyl-CCNU. The time interval
between the low dose (5mgkg- ) and the high dose (50mgkg-1)
was 1 or 2 days Control ---- 5+50mgkg-1, 1 day
* 0; 5+50mgkg-', 2 days U-U; 50+5mgkg-1, 1 day
O O; 50+Smgkg-1, 2 days Fj [1; SSmgkg A A
There were 12 mice/group.
weeks, as compared to 17% mortality in the low-high dose
combinations. Survivors were killed 22 days after treatment,
tissues were wet weighed and examined microscopically.
These results showed increased (or better recovery of)
thymus weight in mice pretreated with the low dose of
methyl-CCNU 1 or 2 days prior to the high dose (Table II).
Also, microscopic examination of the thymus and kidney
showed decreased incidence and degree of hypocellularity in
the thymus and a decrease in the swelling of the tubular
epithelium in the kidneys.
Table I Survival, body weight, corrected organ weight (mgg-I body wt) and morphological changes
determined in mice with low-high and high-low dose combinations ofmethyl-CCNU
Microscopic
Corrected wet weight examination
No. Body
Treatment survivors wt (g) Thymus Kidney Kidney Thymus
Control 12/12 28.6+ 1.9a 1.46+0.28 13.05+0.53
Methyl-CCNU (mgkg-1):
50+5 4/12 19.9+2.7b 1.38+0.36 10.22+0.60b 2/4+c 3/4+ +
5+50 5/12 23.0+2.lb 2.07+0.89 13.48+0.40 1/5+ 1/5+
aValues are mean+s.d. Mice surviving the treatment were killed 40 days after the administration of
the high dose of methyl-CCNU; bSignificantly different from control (P_0.05); cNumber of mice with
pathological change/total number examined. For further details see text.
Table II Body weight and corrected organ weights (mgg - body wt) determined in mice treated with
combinations of low and high (lethal) doses ofmethyl-CCNU
Body weight
Treatment na (g) Thymus Spleen Kidney Testes
Control 10 25.9+2.1b 1.84+0.30 3.12+0.45 12.4+0.7 8.15+0.87
Methyl-CCNU (mgkg 1):
55 4 16.8+2.8c 0.57+0.11c 1.68+0.64c 12.0+ 1.9 3.66+0.98c
50+5; 1 day' 5 16.7+2.1c 0.35+0.16c 2.72+0.99 13.6+ 1.4 3.72+1.22c
5+50; 1 day 10 20.0+1.1Cc 1.12+0.78cc 2.67+0.52 11.7+ 1.2 4.00+1.23c
50+5; 2 days 4 16.8+2.1c 0.52+0.27c 1.98+0.33c 12.6+ 1.4 4.40+0.67c
5+50; 2 days 10 20.3 + 1.8ce 1.02+0.21cc 3.82+ 1.08e 11.7 +3.6 4.05+0.79c
an=number of mice examined; bValues are mean+s.d.; cSignificantly different from untreated controls
(P<0.05); dTime interval between subsequent treatments; eSignificantly different from corresponding high-
low dose combination (P_ 0.05).
.1 -- _ _ _ _ _ _ _
_
_
_
l-268 A. ZIMBER et al.
The effect of low dose of methyl-CCNU administered prior to
a lethal dose ofmelphalan in normal mice In this experiment
low doses (5 and 10mgkg-1) of methyl-CCNU were given 1,
2 or 3 days prior to a lethal dose (20mgmg-1) of
melphalan, which when given alone caused 100% mortality
within 7 days (Figure 2). Mice pretreated with low doses of
methyl-CCNU showed reduced mortality rate. When given
one day apart, a 42% survival was evident in the mice
primed with 5mgkg- I methyl-CCNU. When the time
interval was extended to 2 days the best effect (50%
survival) was obtained when using 10mgkg-1 as a priming
dose. Priming with 5 or 10mgkg-1 3 days before melphalan
had only a slight effect on survival. Based on these results,
the effect of priming of mice with 10mgkg 1 methyl-CCNU
2 days before treatment with 15mgkg 1 melphalan was
studied. Results of this experiment (data not shown) showed
that this treatment increased the survival (13/20 in melphalan
alone group vs. 20/22 in methyl-CCNU primed mice) and
enhanced the recovery of thymus weight. Corrected thymus
wet weights were 1.95+0.43, 0.73+0.46 and 1.13+0.33 in
control, melphalan treated and methyl-CCNU primed and
melphalan treated mice, respectively.
The effect oflow-high dose combinations ofmethyl-CCNU in
the treatment ofLewis lung carcinoma
Since priming of mice with low doses of methyl-CCNU
showed a protective effect against lethal doses in healthy
mice, it was of interest to test whether high doses of methyl-
CCNU would be also well tolerated in mice previously
implanted with a tumour, and whether a therapeutic gain
might be achieved with low-high dose regimens. This could
happen if normal tissues would be protected by the priming
low dose while the tumour would not (Millar et al., 1982).
We first used doses of methyl-CCNU which were higher
than those previously used by us in experimental tumour
systems (Peled et al., 1982; Perk et al., 1974; 1977). Mice
were implanted s.c. with 1 x 106 3LL tumour cells and
treated 10 days later (when tumour size was -0.5-1.0cm3)
with 45 or 40mgkg-1 methyl-CCNU, and combinations of
40 and 5 (high-low) and 5 and 40mgkg-1 (low-high). It
appeared, however, that these doses were toxic: 30-60% of
the treated mice died without tumours 6-25 days following
treatment with methyl-CCNU. Mortality rate was signifi-
cantly decreased with the low-high combination as compared
to the high-low dose combination and to treatment with
45mgkg-1 (which caused the highest mortality), but was not
different from that observed in mice with 40mgkg-1 methyl-
CCNU. Overall, there was no beneficial effect of priming
with the low dose on tumour growth. We then tested the
effect of 35mgkg-1 methyl-CCNU as the high, tumour
killing dose, and the low-high dose combinations of 5 and
35mgkg- administered 2 days apart. Results of this
experiment are illustrated in Figure 3. All the untreated
tumour inoculated mice died within 30 days (MST was 18
days). In contrast, mice treated with 35mgkg-1 or with
35mgkg-1 followed 2 days later by 5mgkg-1 showed
longer survival (MST was 35 and 37 days, respectively).
Following a temporary shrinking of the tumours for - 11-18
days a new burst of tumour growth took place, which caused
death within 34-58 days following tumour inoculation. The
most pronounced effect was observed in the low-high dose
group with MST of 44 days. However, even in this group
10/12 mice died within 60 days after tumour inoculation,
with lung metastases in most animals and, occasionally,
metastases in other organs (i.e. kidney, liver).
Double treatment with low and high dose combinations of
methyl-CCNU
In two experiments mice were treated twice with high dose of
methyl-CCNU and with low-high and high-low dose
combinations. The time interval between the high and low
doses was two days. In the first experiment an initial high
dose of 30mgkg-1 methyl-CCNU was administered on day
9 and a second high dose on day 20 following s.c.
inoculation of 2 x 105 3LL tumour cells. A low dose
(5mgkg-1) was administered 2 days before or after the high
dose. In this experiment there was no difference between the
low-high vs. the high-low combinations until day 40, but
survival at 50 days was 2/10 in the low-high combination as
compared to 6/10 in the high-low dose combination. At 60
days there were 2/10 survivors in both groups. Rate of death
was much faster in the group treated twice with the high
dose alone; MST was 30 days as compared to 41 and 44
days in the low-high and high-low dose combinations,
respectively. All the untreated tumour-inoculated control
mice died within 20 days following inoculation. This
experiment was then repeated using 30mgkg-1 as the high
dose, given 7 and 18 days after tumour inoculation, and
either 5 or 10mgkg-1 methyl-CCNU as the low dose.
Results of this experiment (Table III) showed decreased
toxicity, decreased rate of tumour development and increased
lifespan in the low-high dose treated mice receiving
5mgkg-1, as compared to all other drug treatments which
showed a similar increase in lifespan. Mortality in this
experiment was mostly due to toxicity until day 46. Non-
treated tumour-inoculated mice died 18+2 days after
tumour inoculation. Treatment with high dose of methyl-
CCNU plus vehicle administration 2 days afterwards served
as control. At 90 days there were three survivors in the
group primed with 5mgkg-1 and one survivor in the group
primed with 10mgkg-1 methyl-CCNU, and all these mice
were without tumours on macroscopic and microscopic
examination.
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Figure 2 Percent survival of mice pretreated with low dose
(Smgkg-1 0 * and 10mgkg- 1 0 0) of methyl-CCNU
at 1, 2 or 3 days prior to the administration of a lethal dose
(20mgkg-1) of melphalan. There were 10 to 12 mice/group.
None survived the treatment with melphalan alone.
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Figure 3 Mortality rate of mice implanted s.c. with Lewis lung
carcinoma cells and treated with low and high dose combinations
of 5 and 35mgkg-1 of methyl-CCNU. There were 12 mice/
group. The time interval between the low and high dose adminis-
tration was 2 days.
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Table III Summary of results on toxic deaths and tumour
development in mice treated twice with high dose of methyl-CCNU
and with low-high and high-low dose combinations
Days after tumour inoculation
Treatment 18 32 46 90
None 3/10 (3)a 0 0 0
2.0-3.ob
Methyl-CCNU (mgkg 1):
30 10/10 (4) 4/10 (3) 3/10 (3) 0
0.1-0.4 0.2-1.5 0.2-2.2
30+vehicle 10/10 (6) 5/10 (2) 2/10 (2) 0
0.1-0.4 1.0-2.0 0.3-0.5
5+30 10/10 (1) 7/10 (0) 3/10 (0) 3/10 (0)
0.1
10+30 10/10 (0) 2/10 (0) 1/10 (0) 1/10 (0)
30+5 10/10 (2) 1/10 (0) 0 0
0.1
30+ 10 9/10 (4) 0/10- 0 0
0.1-0.2
aNumber of survivors/total number of mice examined (number of
mice with palpable tumours is given in parentheses); bRange of
tumour wet weight (g).
Discussion
The results herein show that priming with low doses of
methyl-CCNU at appropriate times before treatment with a
high dose can reduce its toxicity in normal and in 3LL
tumour bearing mice, and that this protocol does not protect
the tumour. Thus, 5 or 10mgkg-1 methyl-CCNU adminis-
tered 1 or 2 days prior to lethal doses, markedly decreased
mortality, enhanced body weight gain, thymus and kidney
weight and the normal morphology of these organs. More-
over, this treatment was beneficial when employed with
lethal doses of melphalan, another alkylating agent and
widely used anti-cancer drug. Also, and most important, the
combination of low and high doses of methyl-CCNU
appeared to have a therapeutic gain in mice bearing the
rapidly proliferating and highly metastatic 3LL tumour.
Even in experiments with Lewis lung carcinoma in which
lifespan was not significantly increased by priming with a
low dose, this treatment was not worse than the
administration of high dose alone. There was evidence for a
decrease in toxic deaths in tumour-bearing mice treated with
the low-high dose combinations whenever the high doses
administered alone were lethal, this in either single or double
treatment modalities. There was no protection of the tumour
by priming with low doses of methyl-CCNU. This
phenomenon of a beneficial effect of low doses of cytotoxic
anti-cancer drugs administered prior to high doses or prior
to therapeutic or lethal doses of gamma irradiation, was
previously reported by Rose et al. (1975) and by others
(Gregory et al., 1971; Blackett & Aguado, 1979; Millar &
Hudspith, 1976; Millar et al., 1975; 1978b, c,d; 1980). No
mechanistic explanation for this effect has been elucidated
yet. It was suggested that DNA precursors which are
released from dead cells are involved (Millar et al., 1978a).
Since in sheep and man (Millar et al., 1978d; Hedley et al.,
1978) the beneficial effect persists and is actually optimal 7
days after such treatment, when cellular breakdown products
are probably not present in large quantities, one should
postulate another mechanism. Since the protective effect of
low doses of cytotoxic drugs against radiation damage and
death was demonstrated for a variety of drugs, with different
pharmacokinetic behaviour, one may consider the role of
changes in drug metabolism by microsomal enzymes and
thus the availability of drugs or their active metabolites to
target tissues (i.e. bone marrow, intestinal epithelium)
(Conney, 1965; Orrenius et al., 1969; Hill et al., 1975;
Oliverio, 1976). BCNU, a nitrosourea compound and anti-
cancer drug was shown to alter the activity of various
microsomal enzyme systems (Wilson & Larson, 1981). This
occurred, however, 20 days after treatment.
Although the nitrosoureas and other alkylating agents are
considered to be cell non-specific, the DNA synthetic phase
is the most sensitive to their action (Tannock, 1978). What
effect do low doses of such drugs have on the progression of
stem cells and proliferating cells through phases of the cell
cycle is not known. Such treatment may cause the clustering
of some cells in a phase of the cell cycle which is more
resistant to high doses of the drug administered a few days
afterwards (Kobayashi et al., 1981). Millar et al. (1978b,c)
have shown that the protective effect of priming with low
doses of cyclophosphamide (CY) prior to high doses of CY
or radiation is due to faster recovery of bone marrow stem
cells and not to a reduction in the fraction of stem cells
killed. However, it is difficult to distinguish between true
stem cells and cells capable of replication and tissue
'regeneration' following an acute damage (Potten et al.,
1979). Improvement in stem cell survival is more difficult to
demonstrate, as compared to the recovery of more mature
cell populations. Priming with low doses of alkylating agents
such as CY and nitrosoureas, may kill maturing cells (i.e. in
the bone marrow) thus releasing stem cells from their
inhibitory control (Fried et al., 1973). One should note that
priming with low doses of CY was also shown to protect
slowly proliferating cells of the urothelium and the lung
(Millar et al., 1978a; Collis et al., 1980; Evans et al., 1983b).
If cell recovery in both rapidly and slowly dividing cells is
indeed the main event underlying the effect of low doses of
CY, methyl-CCNU and other drugs, one should analyse
repair enzymes, processes, following such treatment. Priming
with low doses of CY was shown to be beneficial in the
treatment of patients with melanoma (Hedley et al., 1978)
and in the treatment of human neoplasms transplanted into
immunodeprived mice (Evans et al., 1983b; 1984). The low-
high dose combinations of nitrosoureas may be especially
suitable in cancer patients. These compounds are very
efficient tumour cell killing drugs (Valeriote et al., 1968)
which are, however, very toxic and are therefore used with
long time intervals - 6 to 8 weeks - between subsequent
treatments (Carter & Livingston, 1982). Administration of
low dose of nitrosoureas prior to the high doses should be
feasible timewise.
A recent report on the inconsistency of the effect of
priming with low doses of CY prior to high doses of
melphalan in mice (Kulkarni et al., 1985) seems to point to
potential difficulties in adopting this approach to man.
However, the multitude of data pointing to a beneficial
effect of such treatment in tumour bearing mice, including
those transplanted with human tumours, calls for further
studies on the effect of low doses of cytotoxic drugs on
different cell populations, according to their stage of differ-
entiation and maturation, and on recovery processes and
drug metabolism.
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